An analysis of results from 3 clinical trials demonstrated that pegaspargase is cost-effective, improved quality-adjusted life-years, and was the dominant therapy in comparisons with native asparagine in multiple scenarios.
Compliance with Food and Drug Administration Amendments Act of 2007 low, not improving.
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
In this study, a young adult was defined as an individual who was 40 years or younger.
Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.
A study evaluated contributions of physical and psychological symptoms, and pre-existing comorbidities to employment status following treatment for breast cancer.
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.
This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.
Please login or register first to view this content.
